SequelSEC

ACTUATE THERAPEUTICS, INC. ACTU

Pharmaceutical Preparations · CIK 0001652935 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$22.50M
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

ACTUATE THERAPEUTICS, INC. (ACTU) reported net income of -$22.23M for the fiscal year ended 2025-12-31. This page shows 3 annual periods of income statement, balance sheet and cash flow figures normalized from ACTUATE THERAPEUTICS, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

ACTUATE THERAPEUTICS, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
RevenueUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailable
Operating income-$22.50M-$25.16M-$24.97M
Net income-$22.23M-$27.29M-$24.74M
Research & development$10.29M$18.68M$21.71M
Weighted-average diluted sharesshares 21.02Mshares 8.37Mshares 1.43M
Pretax incomeUnavailableUnavailableUnavailable
Income tax expense$800$800$0
Diluted EPS$-1.06$-3.26$-17.24
Selling, general & administrativeUnavailableUnavailableUnavailable
General & administrative$12.20M$6.48M$3.27M
Selling & marketingUnavailableUnavailableUnavailable

Balance

ACTUATE THERAPEUTICS, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
Cash & equivalents$13.16M$8.64MUnavailable
Total assets$14.04M$9.32M$3.00M
Current assets$13.64M$9.21M$3.00M
Total liabilities$6.11M$9.21M$8.44M
Current liabilities$5.71M$8.80M$6.92M
Total equity incl. NCI$7.92M$104.19K-$99.63M
Temporary (mezzanine) equityUnavailable$0$94.18M
InventoryUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailable
Accounts payable$1.52M$1.92M$3.42M

Cash flow

ACTUATE THERAPEUTICS, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
Operating cash flow-$19.21M-$21.84M-$21.63M
Capital expendituresUnavailableUnavailableUnavailable
Investing cash flowUnavailableUnavailableUnavailable
Financing cash flow$23.72M$27.53M$4.13M
Net change in cashUnavailableUnavailableUnavailable
Stock-based compensation$6.05M$2.00M$423.54K
Common dividends paidUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailable

Derived

ACTUATE THERAPEUTICS, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
Free cash flowUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailable
Current ratio2.39x1.05x0.43x
Revenue YoY growthUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ACTU in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-K · Filed 2026-03-26View SEC filing
10-Q · Filed 2025-11-13View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.